Cargando…
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome
BACKGROUND: Doxorubicin has been shown to inhibit proliferation of cancer cells through proteolytic activation of CREB3L1 (cAMP response element binding protein 3-like 1), a transcription factor synthesized as a membrane-bound precursor. Upon doxorubicin treatment, CREB3L1 is cleaved so that the N-t...
Autores principales: | Denard, Bray, Pavia-Jimenez, Andrea, Chen, Weina, Williams, Noelle S., Naina, Harris, Collins, Robert, Brugarolas, James, Ye, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482141/ https://www.ncbi.nlm.nih.gov/pubmed/26110425 http://dx.doi.org/10.1371/journal.pone.0129233 |
Ejemplares similares
-
CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy
por: Denard, Bray, et al.
Publicado: (2018) -
Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1
por: Denard, Bray, et al.
Publicado: (2012) -
Sustained Induction of Collagen Synthesis by TGF-β Requires Regulated Intramembrane Proteolysis of CREB3L1
por: Chen, Qiuyue, et al.
Publicado: (2014) -
Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy
por: Lin, Zhengjun, et al.
Publicado: (2022) -
Identification of Creb3l4 as an essential negative regulator of adipogenesis
por: Kim, T-H, et al.
Publicado: (2014)